HC Wainwright & Co. Reiterates Buy on Madrigal Pharmaceuticals, Maintains $390 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating for Madrigal Pharmaceuticals (NASDAQ:MDGL) and maintained a price target of $390.
October 22, 2024 | 11:20 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Madrigal Pharmaceuticals, maintaining a price target of $390. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst can boost investor confidence, potentially leading to a positive short-term impact on MDGL's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100